In 2023, approximately 45% of participant enrollment at the West Virginia University Cancer Institute Clinical Research Unit (WVUCI CRU) was to cooperative group trials. Many of these trials do not include routine sponsor monitoring. Historically, staff at the WVUCI CRU have conducted reviews in preparation for external audits, every 3 years, resulting in small or repeat errors being discovered possibly years later, after multiple cycles.

**Outcomes**
- Historic patient reviews completed Jan 2024. Future monitoring to be completed within 6 weeks of data entry.
- Repeat data errors identified, corrections & reeducation completed:
  - Increased usage of central source data verification & uploaded documents, therefore increased risk in inadvertently uploading PHI. Bi-weekly DM meeting provides opportunity to review repeat errors & complete necessary retraining.
  - Increase in solicited adverse events in Rave, but not identified in the protocol. DMs reminded to flag to research coordinators when documentation is not available in source.
- Improvement on SWOG expectation report from Sep 2023 through to Dec 2023, from 18 late forms to 5 late forms.
- DMs reported more confidence problem solving issues with sample submission; currently no samples pending.

**Lessons Learned**
- Initial phase of reviews was more time consuming than anticipated due to:
  - Uneven distribution trials resulting in uneven workload for providing responses and updates.
  - Back log in data entry due to a long-standing DM, following ~175 patients, retiring earlier than expected, and a new hire requiring training.
  - Locked eCRFs.
- Varied account set-up within EMR, e.g., confirmation of auto-injector rates and b values on an MRI trial.